QualityStocks would like to highlight HST Global, Inc. (OTCBB: HSTC). The company is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer and other life threatening illnesses. HST focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, then developing those drug candidates for commercial use and developing a network of Wellness Centers Worldwide.
In the company’s recent news,
HST Global, Inc. announced that it has met 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. In the press release announcing results, Ronald Howell, President & CEO of HST Global, Inc., stated, “We are encouraged by these results and are looking forward to subjecting the study to more rigorous tests to support eventual commercialization.”
The company has obtained the rights to a pre-clinical outcome-based study using the pre-clinical drug trade named “Salicinium”. This natural substance derived from plants is both an oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies show that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to endure innate immune reactions.
The pre-clinical study proved Salicinium’s efficacy and safety, as well as freedom from adverse toxicities and adverse side-effects. The study concluded that Salicinium is a novel, homeopathic, immune boosting therapy that when used alone in breast cancer, isolated from other cancers, showed an overall response rate of 79% at 33 months.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
